Erasca, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Andres Y. Maldonado from H.C. Wainwright maintained a Buy rating on the stock and has a $20.00 price target.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Andres Y. Maldonado has given his Buy rating due to a combination of factors, primarily the emerging profile of ERAS-0015 as a potentially differentiated pan-RAS “molecular glue” with meaningful early activity. He highlights particularly strong signals in KRAS G12X non-small cell lung cancer and encouraging activity in pancreatic cancer, supported by dose-dependent exposure, deep reductions in ctDNA, and a tolerability profile that suggests clinically relevant target engagement at manageable doses.
He also emphasizes that recent partnerships with Merck and other collaborators extend the combination therapy potential of ERAS-0015, positioning it as a possible backbone agent rather than a stand-alone product. While he acknowledges that the dataset remains early, with reliance on partially unconfirmed responses and the need for longer follow-up and further safety clarity, he views the risk-reward as attractive and keeps his $20 price target unchanged, reflecting confidence in the asset’s strategic and clinical upside.